Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?
-
Published:2023-07-13
Issue:1
Volume:9
Page:
-
ISSN:2374-4677
-
Container-title:npj Breast Cancer
-
language:en
-
Short-container-title:npj Breast Cancer
Author:
Yu JingORCID, da Silva Edaise M.ORCID, La Hae-Sun, Clark Beth Z.ORCID, Fine Jeffrey L.ORCID, Carter Gloria J., Villatoro Tatiana M., Soong T. Rinda, Lee Adrian V.ORCID, Oesterreich SteffiORCID, Basili ThaisORCID, Blanco-Heredia JuanORCID, Selenica Pier, Ye Qiqi, Da Cruz Paula Arnaud, Dopeso HiginioORCID, Gazzo Andrea, Marra AntonioORCID, Pareja FresiaORCID, Reis-Filho Jorge S.ORCID, Bhargava RohitORCID
Abstract
AbstractThis study describes “lobular-like invasive mammary carcinomas” (LLIMCas), a group of low- to intermediate-grade invasive mammary carcinomas with discohesive, diffusely infiltrative cells showing retained circumferential membranous immunoreactivity for both E-cadherin and p120. We analyzed the clinical-pathologic features of 166 LLIMCas compared to 104 classical invasive lobular carcinomas (ILCs) and 100 grade 1 and 2 invasive ductal carcinomas (IDCs). Tumor size and pT stage of LLIMCas were intermediate between IDCs and ILCs, and yet often underestimated on imaging and showed frequent positive margins on the first resection. Despite histomorphologic similarities to classical ILC, the discohesion in LLIMCa was independent of E-cadherin/p120 immunophenotypic alteration. An exploratory, hypothesis-generating analysis of the genomic features of 14 randomly selected LLIMCas and classical ILCs (7 from each category) was performed utilizing an FDA-authorized targeted capture sequencing assay (MSK-IMPACT). None of the seven LLIMCas harbored CDH1 loss-of-function mutations, and none of the CDH1 alterations detected in two of the LLIMCas was pathogenic. In contrast, all seven ILCs harbored CDH1 loss-of-function mutations coupled with the loss of heterozygosity of the CDH1 wild-type allele. Four of the six evaluable LLIMCas were positive for CDH1 promoter methylation, which may partially explain the single-cell infiltrative morphology seen in LLIMCa. Further studies are warranted to better define the molecular basis of the discohesive cellular morphology in LLIMCa. Until more data becomes available, identifying LLIMCas and distinguishing them from typical IDCs and ILCs would be justified. In patients with LLIMCas, preoperative MRI should be entertained to guide surgical management.
Funder
Department of Pathology, University of Pittsburgh Medical Center Breast Cancer Research Foundation U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology
Reference66 articles.
1. Breast Cancer Facts & Figures 2019-2020. (American Cancer Society, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf). 2. Breast Tumours. WHO Classification of Tumours. 5th edn, Vol. 2 (International Agency for Research on Cancer, 2019). 3. Mersin, H., Yildirim, E., Gulben, K. & Berberoglu, U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur. J. Surg. Oncol. 29, 390–395 (2003). 4. Pestalozzi, B. C. et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J. Clin. Oncol. 26, 3006–3014 (2008). 5. Wasif, N., Maggard, M. A., Ko, C. Y. & Giuliano, A. E. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann. Surg. Oncol. 17, 1862–1869 (2010).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|